Company Filing History:
Years Active: 2012-2014
Title: Wolf Reik: Innovator in Epigenetic Research
Introduction
Wolf Reik is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of epigenetics, particularly in the area of DNA modification. With a total of 2 patents, his work has implications for both cancer therapy and somatic cell nuclear transfer.
Latest Patents
Reik's latest patents include groundbreaking methodologies for the demethylation of methylated nucleic acid sequences. The first patent describes a process for demethylating a methylated DNA sequence in a eukaryotic cell. This process utilizes a molecule that contains a first domain exhibiting cytidine deaminase activity and a second domain that provides either specific or non-specific DNA binding activity. These innovative molecules are particularly useful in somatic cell nuclear transfer and cancer therapy. The second patent similarly focuses on the epigenetic modification of nucleic acid sequences in vivo, reinforcing the potential applications of his research in therapeutic settings.
Career Highlights
Wolf Reik has established himself as a leading figure in epigenetic research. His work has not only advanced scientific understanding but has also opened new avenues for medical applications. He is associated with Cellcentric Limited, where he continues to push the boundaries of innovation in this critical field.
Collaborations
Reik collaborates with notable colleagues such as Hugh Morgan and Chun-Fung Chan. Their combined expertise enhances the research efforts at Cellcentric Limited, fostering an environment of innovation and discovery.
Conclusion
Wolf Reik's contributions to epigenetics through his patents and collaborative efforts mark him as a significant inventor in the field. His work holds promise for future advancements in medical therapies and genetic research.